Loading clinical trials...
Loading clinical trials...
Clock Gene Disruption May be an Initial Manifestation of IBD and Celiac .
patients 6-25 years old upon diagnostic evaluation will be recruited . study population will comprise of two groups: newly diagnosed IBD patients/ Celiac disease and healthy controls. upon enrollment, subjects will fill out sleeping habits questioners, demographic data, medical history. blood samples will be drawn for CRP and clock gene expression in systemic WBC. intestinal biopsies will be snap frozen for clock gene extraction and amplification only for patients with IBD.
Age
6 - 25 years
Sex
ALL
Healthy Volunteers
No
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Start Date
August 31, 2017
Primary Completion Date
July 31, 2022
Completion Date
December 31, 2022
Last Updated
February 22, 2023
80
ACTUAL participants
no intervention performed- observational only
OTHER
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06573723